The French translational oncology accelerator, MATWIN, awards the QF-Pro(PD-1/PD-L1) assay as ‘Best Predictive Test’

By 10 de enero de 2021abril 11th, 2021News

The French translational oncology accelerator, MATWIN, awards the QF-Pro(PD-1/PD-L1) assay as ‘Best Predictive Test’

The panel of 20 members, including 13 leading global industrial decision makers in oncology R&D, shortlisted 10 projects based on their promising medical findings and potential for industrial development. Three projects were singled out for special awards by the MATWIN board, based on their potential future development and offering the most promising opportunities for patients in the fight against cancer. 

The project submitted by FASTBASE Solutions’ was elected ‘Best predictive test’ which is an innovative test based on efficient and reliable detection of the PD-1 / PD-L1 interaction for an appropriate selection and stratification of patients eligible for immunotherapies in numerous cancers types

The candidates pitching their projects have a unique opportunity to present their innovation to a panel of renowned international experts; the panels valuable recommendations help move projects forward and promote collaboration opportunities, said Lucia Robert, CEO of MATWIN. Everybody wins the applicants, the industry players and, ultimately, the patients themselves. More in-depth discussions are already ongoing to establish potential partnerships.

About MATWIN : MATWIN is a French open-innovation platform dedicated to promoting innovation in oncology. For over ten years, the platform has offered a six-month support program to help fast-track innovative projects – from both academic laboratories and start-up companies across Europe – and promote partnerships with industrial partners and investors. The program is supported by 13 international laboratories (Amgen, AstraZeneca, BMS, Boehringer Ingelheim, Exact Sciences, Gilead, GSK, Nanostring Technologies, Novartis, Pierre Fabre, Pfizer, Roche and Sanofi) as well as many other organizations working to promote innovation in cancer research (e.g. oncology clusters, technology transfer offices, incubators …).

Since 2015, MATWIN has been a subsidiary of Unicancer, the French federation that brings together the 18 Comprehensive Cancer Centers in France.
www.matwin.fr